Myasthenia Gravis - Global Market Outlook (2017-2026)

Myasthenia Gravis - Global Market Outlook (2017-2026)

  • Published: December 2018
  • ID: SMRC17824

According to Stratistics MRC, the Global Myasthenia Gravis Market is accounted for $1,215.00 million in 2017 and is expected to reach $3,651.25 million by 2026 growing at a CAGR of 13.0% during the forecast period. Increasing health care spending & improving health care infrastructure, increase in occurrence of autoimmune disorders and strong pipeline in its treatment are some of the key factors propelling the market growth. However, limited availability of FDA approved drugs and costly treatment options are some issues restricting the market growth.

Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Moreover, it is characterized by fatigue and weakness of skeletal muscles. Therefore, it occurs in all races, males & females, and at any age. On the other hand MG is not thought to be directly hereditary nor is it transmittable. It does occasionally occur in more than one member of the same family.

Amongst treatment, drug treatment segment commanded considerable market share in the global market owing to the factors responsible for modifying the immune response of the immune system by inhibition of white blood cell activity. Based on geography, Asia Pacific region is expected to register highest market growth rate during the forecast period. Due to Several non-governmental and governmental organizations in the region are concerned in organizing awareness programs
 
Some of the key players in Myasthenia Gravis market include Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceuticals International, Inc., Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies) and Shire plc.  
 
Treatments Covered:
• Rapid Immunotherapies
• Drug Treatment

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan       
    • China       
    • India       
    • Australia 
    • New Zealand     
    • South Korea      
    • Rest of Asia Pacific   
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary  
    
2 Preface   
 2.1 Abstract  
 2.2 Stake Holders 
 2.3 Research Scope 
 2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
 2.5 Research Sources 
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions
    
3 Market Trend Analysis 
 3.1 Introduction 
 3.2 Drivers  
 3.3 Restraints 
 3.4 Opportunities 
 3.5 Threats  
 3.6 Emerging Markets 
 3.7 Futuristic Market Scenario
    
4 Porters Five Force Analysis 
 4.1 Bargaining power of suppliers
 4.2 Bargaining power of buyers
 4.3 Threat of substitutes
 4.4 Threat of new entrants
 4.5 Competitive rivalry 
     
5 Global Myasthenia Gravis Market, By Treatment
 5.1 Introduction 
 5.2 Rapid Immunotherapies
  5.2.1 Thymectomy
  5.2.2 Intravenous Immunoglobulin (IVlg)
  5.2.3 Plasmapheresis
 5.3 Drug Treatment 
  5.3.1 Chronic Immunomodulators
  5.3.2 Monoclonal Antibodies
  5.3.3 Cholinesterase Inhibitors
    
6 Global Myasthenia Gravis Market, By Geography
 6.1 Introduction 
 6.2 North America 
  6.2.1 US 
  6.2.2 Canada 
  6.2.3 Mexico 
 6.3 Europe  
  6.3.1 Germany 
  6.3.2 UK 
  6.3.3 Italy 
  6.3.4 France 
  6.3.5 Spain 
  6.3.6 Rest of Europe
 6.4 Asia Pacific 
  6.4.1 Japan 
  6.4.2 China 
  6.4.3 India 
  6.4.4 Australia 
  6.4.5 New Zealand
  6.4.6 South Korea
  6.4.7 Rest of Asia Pacific
 6.5 South America 
  6.5.1 Argentina
  6.5.2 Brazil 
  6.5.3 Chile 
  6.5.4 Rest of South America
 6.6 Middle East & Africa
  6.6.1 Saudi Arabia
  6.6.2 UAE 
  6.6.3 Qatar 
  6.6.4 South Africa
  6.6.5 Rest of Middle East & Africa
    
7 Key Developments  
 7.1 Agreements, Partnerships, Collaborations and Joint Ventures
 7.2 Acquisitions & Mergers
 7.3 New Product Launch
 7.4 Expansions 
 7.5 Other Key Strategies
    
8 Company Profiling  
 8.1 Novartis AG  
 8.2 Takeda Pharmaceutical Company Limited
 8.3 Grifols, S.A. 
 8.4 Valeant Pharmaceuticals International, Inc. 
 8.5 Alexion Pharmaceutical Inc.
 8.6 F. Hoffmann-La Roche AG
 8.7 CSL Behring 
 8.8 Baxter International, Inc. 
 8.9 Avadel Pharmaceuticals, PLC. (Flamel Technologies)
 8.10 Shire plc   


List of Tables    
1 Global Myasthenia Gravis Market Outlook, By Region (2016-2026) (US $MN)
2 Global Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
3 Global Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
4 Global Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
5 Global Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
6 Global Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
7 Global Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
8 Global Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
9 Global Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
10 Global Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
11 North America Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
12 North America Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
13 North America Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
14 North America Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
15 North America Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
16 North America Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
17 North America Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
18 North America Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
19 North America Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
20 North America Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
21 Europe Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
22 Europe Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
23 Europe Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
24 Europe Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
25 Europe Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
26 Europe Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
27 Europe Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
28 Europe Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
29 Europe Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
30 Europe Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
31 Asia Pacific Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
32 Asia Pacific Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
33 Asia Pacific Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
34 Asia Pacific Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
35 Asia Pacific Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
36 Asia Pacific Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
37 Asia Pacific Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
38 Asia Pacific Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
39 Asia Pacific Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
40 Asia Pacific Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
41 South America Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
42 South America Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
43 South America Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
44 South America Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
45 South America Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
46 South America Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
47 South America Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
48 South America Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
49 South America Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
50 South America Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
51 Middle East & Africa Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
52 Middle East & Africa Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
53 Middle East & Africa Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
54 Middle East & Africa Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
55 Middle East & Africa Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
56 Middle East & Africa Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
57 Middle East & Africa Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
58 Middle East & Africa Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
59 Middle East & Africa Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
60 Middle East & Africa Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials